(Q40615805)

22 September 2017

title

The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens (English)

1 reference

22 September 2017

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

3 April 2024

author name string

Danijela Jelovac

2

1 reference

22 September 2017

Brian Long

3

1 reference

22 September 2017

Angela H. Brodie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623522

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623522

3 April 2024

publication date

1 September 2003

1 reference

full work available at URL

22 September 2017

https://api.elsevier.com/content/article/PII:S0960076003003686?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

https://api.elsevier.com/content/article/PII:S0960076003003686?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

The Journal of Steroid Biochemistry and Molecular Biology

3 April 2024

published in

1 reference

22 September 2017

volume

86

1 reference

22 September 2017

issue

3-5

1 reference

22 September 2017

page(s)

283-288

1 reference

Plasma Precursors of Estrogen. II. Correlation of the Extent of Conversion of Plasma Androstenedione to Estrone with Age1

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

The effects of aromatase inhibitors and antiestrogens in the nude mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

Aromatase inhibitors and their antitumor effects in model systems

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2803%2900368-6

7 January 2021

Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue

2

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00368-6

3 April 2024

Identifiers

1 reference

22 September 2017

1 reference